| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0264-410X(03)00073-2 |
| P698 | PubMed publication ID | 12686095 |
| P2093 | author name string | Wood JM | |
| Levandowski RA | |||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | influenza vaccine | Q383260 |
| P304 | page(s) | 1786-1788 | |
| P577 | publication date | 2003-05-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | The influenza vaccine licensing process. | |
| P478 | volume | 21 |
| Q30151861 | A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016). |
| Q33931916 | A single dose of whole inactivated H7N9 influenza vaccine confers protection from severe disease but not infection in ferrets |
| Q83139703 | Active surveillance for influenza vaccine adverse events: the integrated vaccine surveillance system |
| Q41347626 | Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection |
| Q41224885 | Automated Imaging and Analysis of the Hemagglutination Inhibition Assay |
| Q30364635 | Considerations for the rapid deployment of vaccines against H7N9 influenza. |
| Q30382947 | Continuous cell lines as a production system for influenza vaccines. |
| Q37444287 | Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. |
| Q35952784 | Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system |
| Q90280392 | DNA vaccine based on conserved HA-peptides induces strong immune response and rapidly clears influenza virus infection from vaccinated pigs |
| Q30365932 | Determinants of influenza transmission in South East Asia: insights from a household cohort study in Vietnam |
| Q57093727 | Development of a Pan-H1 Influenza Vaccine |
| Q97530848 | Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs |
| Q30415924 | Guillain-Barré syndrome after exposure to influenza |
| Q28291850 | Guillain-Barré syndrome after exposure to influenza virus |
| Q36139178 | Impact of Adjuvants on the Immunogenicity and Efficacy of Split-Virion H7N9 Vaccine in Ferrets |
| Q30367695 | Influenza vaccines: a moving interdisciplinary field. |
| Q30369109 | Intranasal immunization of recombinant Lactococcus lactis induces protection against H5N1 virus in ferrets. |
| Q36354085 | Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine |
| Q89723360 | Next-generation influenza vaccines: opportunities and challenges |
| Q26995797 | Phage cocktails and the future of phage therapy |
| Q34778408 | Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review |
| Q35919119 | Progress in the development of a cervical cancer vaccine. |
| Q30382787 | Protection against H5N1 Influenza Virus Induced by Matrix-M Adjuvanted Seasonal Virosomal Vaccine in Mice Requires Both Antibodies and T Cells. |
| Q41497402 | Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies |
| Q35218808 | Quantitative review of antibody response to inactivated seasonal influenza vaccines |
| Q45375451 | Rapid typing and subtyping of vaccine strains of the influenza virus with high resolution mass spectrometry |
| Q33538308 | Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model |
| Q34194336 | Serologic assays for influenza surveillance, diagnosis and vaccine evaluation |
| Q50784339 | The European CHMP criteria for influenza vaccine immunogenicity cannot be improved by the use of confidence intervals. |
| Q57923584 | The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure? |
| Q58382401 | The application of pseudotypes to influenza pandemic preparedness |
| Q36131193 | The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines |
| Q28262476 | The virosome concept for influenza vaccines |
| Q42984516 | Viral vaccine meeting held in Barcelona, October 25-28, 2003. |
Search more.